Polaris Capital Management, LLC on Cytokinetics, Incorporated
Thesis
Polaris added Cytokinetics after FDA approval of Myqorzo for hypertrophic cardiomyopathy. The manager views Myqorzo as superior to Bristol Myers Squibb's Camzyos because it offers better symptom relief with simpler dosing. That perceived product advantage creates an opportunity for Cytokinetics to establish a meaningful position in the cardiomyopathy market. The investment therefore rests on translating regulatory approval and product differentiation into successful commercialization.
“We added Cytokinetics to our portfolio, a U.S. biopharma company with FDA approval for Myqorzo for hypertrophic cardiomyopathy”
Key risks
- Myqorzo commercialization is weaker than expected
- Competitive positioning versus Camzyos deteriorates
- Regulatory or clinical setbacks affect the product franchise